MedTrace Logo

A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)

NCT00004845 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2009-12-11

No results posted yet for this study

Summary

The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Rofecoxib

DRUG

Naproxen

Sponsors & Collaborators

  • Alzheimer's Disease Cooperative Study (ADCS)

    collaborator OTHER

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • Leon Thal, MD · Alzheimer's Disease Cooperative Study

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2001-12-31
Completion
2001-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004845 on ClinicalTrials.gov